Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis

To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on PRIMSA g...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-06, Vol.13 (1), p.9893-9893, Article 9893
Main Authors: Zhou, Qian, Zeng, Furong, Meng, Yu, Liu, Yihuang, Liu, Hong, Deng, Guangtong
Format: Article
Language:English
Subjects:
631/250/590
692/699/255/1901
692/699/255/2514
COVID-19
COVID-19 - complications
COVID-19 - prevention & control
COVID-19 Vaccines
Hepatitis B Vaccines
HIV
HIV Infections - complications
Human immunodeficiency virus
Humanities and Social Sciences
Humans
Immunization
Meta-analysis
multidisciplinary
Public health
Science
Science (multidisciplinary)
Seroconversion
Vaccination - methods
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library were searched for eligible studies to perform a systematic review and meta-analysis based on PRIMSA guidelines. The pooled rate and risk ratio of seroconversion were assessed using the Freeman-Tukey double arcsine method and Mantel–Haenszel approach, respectively. Random-effects model was preferentially used as the primary approach to pool results across studies. A total of 50 studies involving 7160 patients living with HIV were analyzed. We demonstrated that only 75.0% (56.4% to 89.9%) patients living with HIV achieved a seroconversion after uncomplete vaccination, which improved to 89.3% (84.2% to 93.5%) after complete vaccination, and 98.4% (94.8% to 100%) after booster vaccination. The seroconversion rates were significantly lower compared to controls at all the stages, while the risk ratios for uncomplete, complete, and booster vaccination were 0.87 (0.77 to 0.99), 0.95 (0.92 to 0.98), and 0.97 (0.94 to 0.99), respectively. We concluded that vaccine doses were associated with consistently improved rates and risk ratios of seroconversion in patients living with HIV, highlighting the significance of booster vaccination for patients living with HIV.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-37051-x